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Abstract
In the 9th ETA-CRN Meeting (September 2009, Lisbon) some recommendations from the American Thyroid
Association (ATA) guidelines for the management of medullary thyroid cancer (MTC) were discussed by an
European Panel of Experts (EPE). Among the 12 ATA recommendations related to hereditary MTC and to the
optimal range of RET mutations to be tested (recommendations 1-5 and 9-15), 7 were shared and 5 were not
shared by the EPE. In the present paper, the related comments and suggestions will be reported and discussed.
Introduction
In the 9th ETA-CRN Meeting (September 2009, Lisbon)
some recommendations from the American Thyroid
Association (ATA) guidelines for the management of
medullary thyroid cancer (MTC) [1] were discussed by
an European Panel of Experts (EPE). In the present
paper, the comments risen on ATA recommendations
(ATA-R) related to hereditary MTC and to the optimal
range of RET mutations to be tested will be reported and
discussed (Additional file 1).
European comments to ATA-R 1-5 and 9-15
ATA recommendations shared by the EPE
All experts fully agreed with the need to perform RET
testing in subjects at risk for autosomal dominant inheri-
tance of MEN 2 (multiple endocrine neoplasia type 2) or
FMTC (Familial Medullary Thyroid Cancer) and, in parti-
cular, shortly after birth for MEN 2B and before 5 years of
age for MEN 2A and FMTC (ATA-R #3). Agreement was
also found about the need for a pre- and post-RET testing
expert genetic counseling (ATA-R #5) and it was stated
that a list of European laboratories should probably be
useful for patients. Nevertheless, though at the Orphanet
EuroGentest website (http://www.orpha.net/consor/cgi-
bin/index.php) more than 100 European laboratories are
listed, this is probably far to be the complete list, also con-
sidering that it largely changes over times. No concerns
were risen about the need to offer RET mutation analysis
to all first-degree relatives of known mutation carriers
(ATA-R #9). The topic of ATA-R #12 relates to the indi-
cation for the sequencing of the entire coding region of
RET in patients with MEN 2 and negative for mutations
in exons 8, 10, 11, 13-16. It should be underlined that the
remaining 13 exons (1-7, 9, 12, 17-21) have never been
found to be mutated [2]. Nevertheless, though this
approach was considered poorly cost effective, most
experts and the 46% of the participants agreed with the
ATA indications, since rare mutations comprise up to
30% of all hereditary cases, based on the literature data
[3-5]. An additional recommendation would be to start
the analysis of the additional regions of the gene from
exon 5, which has been reported to be mutated (G321R)
[6]. Strictly related to this topic, the possibility to analyze,
in this category of patients, pheocrocytoma (PHAEO)-
related genes was also discussed. The background was that
40-45% of apparently sporadic PHAEO or paragangliomas
are hereditary and germline mutations are found in VHL
(von Hippel-Lindau tumor suppressor, E3 ubiquitin
protein ligase), SDHB/C/D (succinate dehydrogenase
complex, subunit B, subunit C, subunit D) and RET (ret
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proto-oncogene) [7]. Nevertheless, the prevalence of
mutated cases is extremely variable among different Coun-
tries, and in particular very low for the RET gene. This
must be considered when the decision is taken to analyze
PHAEO-related genes in RET negative cases.
In the clinical setting of MEN 2B, since virtually all
patients harbor mutations in exons 15 and 16 (A883F and
M918T, respectively), the panel agreed with ATA indica-
tion to analyze both exons and to test the entire RET cod-
ing region if those 2 exons are negative for mutations
(ATA-R #13 and #14). Finally, total agreement was also
expressed regarding the ATA-R #15 which indicates to
treat MEN 2B patients harboring codon 804 mutation
associated to another mutation similarly to those with the
more typical MEN 2B RET causing mutations. Indeed,
data from the literature report that the phenotype asso-
ciated to V804M mutation alone is mostly FMTC [8,9],
though also MEN 2A cases have been described [9-11].
However, when this mutation is associated to another on
the same allele (Y806C, S904C, E805K, V778I) the pheno-
type resembles that of MEN 2B [12-16].
ATA recommendations not shared by the EPE
The ATA-R #1, related to the indication to offer the
germline RET testing to all patients with a personal
medical history of primary C cell hyperplasia (CCH),
MTC, or MEN2, was extensively discussed. In particular,
while no concerns were risen about the need to perform
RET analysis in a patient with MEN, it was observed
that RET mutations are extremely rare in patients with
CCH (0.03%), as reported by Scheuba et al. in 2009 [17].
Thus, the genetic analysis was not considered cost-effec-
tive for CCH cases by about half of the EPE, though the
indication to recommend it was shared by other experts
and by the majority of the participants. Similarly, there
were some pros and cons also regarding apparently
sporadic MTC. On one hand, the presentation of spora-
dic and familial-non MEN2A /2B- forms is almost iden-
tical and they cannot be differentiated on a clinical
basis. Moreover, it has been reported that 6.5-10% of
apparently sporadic cases are indeed hereditary forms
[6,18]. On the other hand, it was outlined that the
extensive and non-selective use of RET testing could
lead to a stop in the reimbursement of the genetic
screening (at least of the less involved exons) by the
National Health Care Systems in patients with MTC,
citing a lack of evidence to suggest hereditary disease
[19]. The final recommendation was thus to modulate
RET testing in apparently sporadic MTC according to
clinical data and the local General Health System.
The ATA-R #11 is related to the identification of the
optimal range of RET mutations to be tested. Most of
the experts and about half of the participants suggested
to extend the analysis to exon 8, at least in all regions
where mutations in that exon have been described,
always in non MEN 2A/2B hereditary MTCs (Brazil,
Greece, France, Italy) [20-23].
ATA-R #10 (grade A) suggests to perform the testing
of exon 10 in individuals with Hirschprung disease
(HSCR), in order to detect families with activating
mutations 618 o 620 in whom HSCR and MEN 2A are
associated. Nevertheless, it should be highlighted that
this association is frequent for MEN 2A (25-40% of
families), but it is rare (2%) [24] in a very common dis-
ease such as HSCR, which has been related to mutations
in at least 10 different genes. RET testing was thus con-
sidered to be not cost-effective and most experts indi-
cated to downgrade this recommendation, and proposed
to test HSCR patients for basal Ct.
Another important topic was related to the lichen pla-
nus amyloidosis, in the presence of which ATA guide-
lines recommend (#4, grade C) to perform the RET
genetic testing for 634 mutation. The EPE and the large
majority of participants proposed to upgrade this
recommendation based on the data of the literature
showing that this early cutaneous manifestation is more
frequent than previously suspected, being present in up
to 36% of MEN 2A cases [25]. In addition, lichen planus
has been associated not only to codon 634, but also to
codon 804 mutations [26]. Thus, the presence of lichen
planus amyloidosis or pruritis in the central upper back
should prompt Ct measurement in adults and genetic
testing in children, possibly after 4 mm punch biopsy
and staining with thioflavin T in order to identify amy-
loid deposits.
ATA-R #2 (grade B) is related to the indication to
perform RET testing in cases of intestinal ganglioneuro-
matosis. The background refers to data reporting that in
MEN 2B, de novo mutations are extremely more fre-
quent (50-90%) than for the other familial MTCs (2-9%)
[27]. For this reason, the early diagnosis of MEN 2B in
several cases cannot be based on familial RET screening.
Moreover, extrathyroidal MEN 2B symptoms develop
age dependently, and, though the majority of the “clas-
sic” symptoms is not expressed before 4-6 years of age,
ganglioneuromatosis is always present and it is one of
the earliest signs [28]. In keeping with the general agree-
ment that in MEN 2B the clinical diagnosis of the syn-
drome is crucial, EPE was concordant in the indication
to perform the RET screening in cases presenting with
one or more signs related to the syndromes, such as
ganglioneuromatosis, but also bumpy lips with mucosal
neuroma, and corneal nerves thickening (with a preva-
lence of 69% in MEN 2B and 29% in MEN 2A) [29,30].
Another crucial sign, not reported in the ATA guide-
lines, is the tearless crying which can be recognized in
more than 85% of the MEN 2A/B infants and which
seems to be one of the most promising signs [27],
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though more data are likely needed to include this manifes-
tation as indication for RET testing in infants without any
other MEN 2 symptoms and with negative family history.
Finally, the EPE discussed the opportunity to include
some recommendation about RET polymorphism, not
reported in the ATA guidelines. Conflicting results have
been published in recent years about the possible role of
RET polymorphisms as genetic modifiers either in spora-
dic or hereditary MTC. In particular, and only considering
familial MTCs, an association between G691S and S904S
with an earlier age at onset in MEN2A [31] was observed,
in patients with the V804M mutation, the association
between L769L and earlier age of onset was reported [32],
whereas in patients with G533C mutation, the variant
IVS1-126G > T was found to be associated with age at
diagnosis and IVS8 +82A > G; 85-86 insC with node
metastases at diagnosis [33]. More recently, the RET
S836S variant has been found to be associated with early
onset and increased risk for metastatic disease [34]. Never-
theless, the data available to date have not been signifi-
cantly replicated and discordant data have been obtained
in different series [35]. Thus, the EPE and most of the
participants supported the idea to draw a recommendation
highlighting the lack of clinical significance of poly-
morphic variants.
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